These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 25319658)
1. Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions. Koldehoff M Methods Mol Biol; 2015; 1218():277-92. PubMed ID: 25319658 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. Koldehoff M; Elmaagacli AH Methods Mol Biol; 2009; 487():451-66. PubMed ID: 19301661 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Koldehoff M; Steckel NK; Beelen DW; Elmaagacli AH Clin Exp Med; 2007 Jun; 7(2):47-55. PubMed ID: 17609876 [TBL] [Abstract][Full Text] [Related]
4. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639 [TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Scherr M; Chaturvedi A; Battmer K; Dallmann I; Schultheis B; Ganser A; Eder M Blood; 2006 Apr; 107(8):3279-87. PubMed ID: 16278304 [TBL] [Abstract][Full Text] [Related]
6. Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model. Chaturvedi A; Battmer K; Schaefer D; Ganser A; Eder M; Scherr M Oligonucleotides; 2007; 17(1):22-34. PubMed ID: 17461760 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247 [TBL] [Abstract][Full Text] [Related]
8. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia. Zhu XS; Lin ZY; Du J; Cao GX; Liu G Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540 [TBL] [Abstract][Full Text] [Related]
9. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481 [TBL] [Abstract][Full Text] [Related]
10. Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation. Shen Q; Liu S; Chen Y; Yang L; Chen S; Wu X; Li B; Lu Y; Zhu K; Li Y J Hematol Oncol; 2013 Sep; 6():64. PubMed ID: 24004697 [TBL] [Abstract][Full Text] [Related]
11. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function. Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074 [TBL] [Abstract][Full Text] [Related]
12. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells. Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961 [TBL] [Abstract][Full Text] [Related]
13. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169 [TBL] [Abstract][Full Text] [Related]
14. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Wohlbold L; van der Kuip H; Miething C; Vornlocher HP; Knabbe C; Duyster J; Aulitzky WE Blood; 2003 Sep; 102(6):2236-9. PubMed ID: 12750174 [TBL] [Abstract][Full Text] [Related]
16. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells. Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755 [TBL] [Abstract][Full Text] [Related]
17. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells. Zhang JH; He YL; Zhu R; Du W; Xiao JH Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894 [TBL] [Abstract][Full Text] [Related]